Default company panoramic image

Gradient Therapeutics, Inc.

Our disruptive medical device will treat severe PH; supported by recent clinical data, it will improve quality of life and reduce costs to patients.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location San Francisco, CA, US
  • Currency USD
  • Founded April 2013
  • Employees 5
  • Website

Company Summary

Gradient is developing a novel trans-vascular, catheter based technology based on proven clinical, human data to treat pulmonary hypertension (PH), a fatal condition that affects approximately 500,000 patients per year worldwide. This disruptive therapy results in reduced pulmonary vascular resistance and improvement in cardiovascular hemodynamics, symptoms, and costs of care, and has shown breakthrough potential as a life-saving treatment.


  • D4d2dffe 9d53 4d25 9a5d ac575e0a20d5
    President and Founder

    BioDesign Surgical Innovation Fellow at Stanford. Has prior catheter device development experience, having aided development of a novel, catheter based drug delivery system for stem cell transplantation to the heart through engineering work for Silicon Valley Surgical, Inc. Previously co-founded a medical device company in the cardiac surgery and interventional cardiology space named Transapical Interventions, Inc.

  • 8d4ae182 33e7 421a 9f82 470f438ba934
    CTO and Co-Founder

    Engineer specializing in early stage med devices with over 25 years experience in catheter development, former principal of Silicon Valley Surgical. Has worked with Baxter, ACS, Guidant, Boston Scientific, and numerous medical device start-up companies. Over 20 issued medical device patents.

  • F348d40c 4f8d 4774 bc21 563793b64af6
    CMO, Acting CEO and Co-Founder

    Associate Professor of Pediatrics, and by courtesy, BioEngineering; Director of the Vera Moulton Wall Center for Pulmonary Vascular Disease and Pediatric Pulmonary Hypertension program at Stanford. Over 15 years experience performing pediatric and congenital interventional cardiac catheterization. Extensive history of governmental, industry and investigator initiated research studies.

  • F98ddeec f491 44f8 8c1f b5a9a41d3322
    Director of Clinical Marketing

    Former Healthcare Consultant (Accenture) and Clinical Research Coordinator, Stanford Pediatric Cardiology. M.D. candidate, 2018.